| Product Code: ETC4640018 | Publication Date: Nov 2023 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 60 | No. of Figures: 30 | No. of Tables: 5 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Ireland Orphan Drugs Market Overview |
3.1 Ireland Country Macro Economic Indicators |
3.2 Ireland Orphan Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 Ireland Orphan Drugs Market - Industry Life Cycle |
3.4 Ireland Orphan Drugs Market - Porter's Five Forces |
3.5 Ireland Orphan Drugs Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.6 Ireland Orphan Drugs Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.7 Ireland Orphan Drugs Market Revenues & Volume Share, By Therapy Class, 2021 & 2031F |
4 Ireland Orphan Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of rare diseases in Ireland |
4.2.2 Favorable government initiatives to promote orphan drug development |
4.2.3 Rising healthcare expenditure and focus on personalized medicine |
4.3 Market Restraints |
4.3.1 High cost associated with orphan drugs |
4.3.2 Limited patient pool for rare diseases in Ireland |
4.3.3 Stringent regulatory requirements for orphan drug approval |
5 Ireland Orphan Drugs Market Trends |
6 Ireland Orphan Drugs Market Segmentations |
6.1 Ireland Orphan Drugs Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 Ireland Orphan Drugs Market Revenues & Volume, By Revlimid, 2021-2031F |
6.1.3 Ireland Orphan Drugs Market Revenues & Volume, By Rituxan, 2021-2031F |
6.1.4 Ireland Orphan Drugs Market Revenues & Volume, By Opdivo, 2021-2031F |
6.1.5 Ireland Orphan Drugs Market Revenues & Volume, By Keytruda, 2021-2031F |
6.1.6 Ireland Orphan Drugs Market Revenues & Volume, By Imbruvica, 2021-2031F |
6.1.7 Ireland Orphan Drugs Market Revenues & Volume, By Soliris, 2021-2031F |
6.2 Ireland Orphan Drugs Market, By Drug Type |
6.2.1 Overview and Analysis |
6.2.2 Ireland Orphan Drugs Market Revenues & Volume, By Biologics, 2021-2031F |
6.2.3 Ireland Orphan Drugs Market Revenues & Volume, By Non-Biologics, 2021-2031F |
6.3 Ireland Orphan Drugs Market, By Therapy Class |
6.3.1 Overview and Analysis |
6.3.2 Ireland Orphan Drugs Market Revenues & Volume, By Oncology, 2021-2031F |
6.3.3 Ireland Orphan Drugs Market Revenues & Volume, By Blood, 2021-2031F |
6.3.4 Ireland Orphan Drugs Market Revenues & Volume, By Endocrine, 2021-2031F |
6.3.5 Ireland Orphan Drugs Market Revenues & Volume, By Central Nervous Systems, 2021-2031F |
6.3.6 Ireland Orphan Drugs Market Revenues & Volume, By Cardiovascular, 2021-2031F |
6.3.7 Ireland Orphan Drugs Market Revenues & Volume, By Respiratory, 2021-2031F |
7 Ireland Orphan Drugs Market Import-Export Trade Statistics |
7.1 Ireland Orphan Drugs Market Export to Major Countries |
7.2 Ireland Orphan Drugs Market Imports from Major Countries |
8 Ireland Orphan Drugs Market Key Performance Indicators |
8.1 Number of orphan drug designations granted in Ireland |
8.2 Adoption rate of orphan drugs in the Irish healthcare system |
8.3 Investment in research and development for rare diseases in Ireland. |
9 Ireland Orphan Drugs Market - Opportunity Assessment |
9.1 Ireland Orphan Drugs Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.2 Ireland Orphan Drugs Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.3 Ireland Orphan Drugs Market Opportunity Assessment, By Therapy Class, 2021 & 2031F |
10 Ireland Orphan Drugs Market - Competitive Landscape |
10.1 Ireland Orphan Drugs Market Revenue Share, By Companies, 2024 |
10.2 Ireland Orphan Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations | 13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here